Every 10-Q that Fulgent Genetics, Inc. (FLGT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FLGT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FLGT filings page.
Fulgent Genetics (FLGT) filed its Q3 2025 10‑Q, showing higher revenue but continued losses as it invests in growth and therapeutics. Revenue rose to $84.1M from $71.7M a year ago, lifting gross profit to $35.5M. Operating loss narrowed year over year to $15.4M, and net loss attributable to Fulgent was $6.6M (basic and diluted EPS ($0.21)). For the nine months, revenue reached $239.3M with a net loss of $37.1M.
The laboratory services segment generated nearly all revenue; one customer accounted for 23% of quarterly sales. The therapeutic development segment recorded modest revenue and a meaningful adjusted operating loss as programs advance. The company recognized a $9.9M impairment on a non‑marketable equity investment during 2025.
Liquidity remained solid: cash and cash equivalents were $117.6M, with marketable securities of $258.2M short‑term and $411.8M long‑term as of September 30, 2025. Total assets were $1.21B against total liabilities of $93.8M. Operating cash flow was a use of $23.5M year‑to‑date, partly offset by $100.2M net cash provided by investing activities. The company repurchased $10.9M of common stock year‑to‑date. As of November 3, 2025, shares outstanding were 30,912,392.
Fulgent Genetics (FLGT) Q2-25 10-Q highlights
- Revenue: $81.8 m, up 15% YoY; 1H-25 revenue $155.3 m (+15%). Precision Diagnostics remains the largest line ($47.3 m, 58%).
- Gross margin: 42.1% vs 37.3% prior-year as cost discipline in laboratory services offsets mix shift.
- Operating loss: –$19.7 m (vs –$18.9 m). Operating expenses rose 19% to $54.1 m on higher G&A (+24%) and marketing spend (+43%).
- Net loss attributable to shareholders: –$19.0 m (EPS –$0.62) vs –$8.7 m (–$0.29). 1H-25 EPS –$0.99.
- Impairment: $9.9 m write-down of Helio Genomics investment drove other expense; without it, other income was $8.1 m interest.
- Cash & investments: $777 m (cash + marketable securities) with $87.9 m cash vs $55.1 m YE-24. Long-term securities declined $86 m as durations shortened; total assets $1.2 bn.
- Operating cash flow: –$34.6 m vs +$11.6 m prior year, due mainly to $33 m federal tax payments and higher receivables.
- Share activity: Repurchased $13.9 m stock YTD; share count 30.6 m.
- Customer concentration: One institutional customer accounted for 22% of Q2 revenue and 29% of receivables.
- Regulatory matters: DOJ CIDs on lab billing and HRSA audit remain open; SEC investigation closed with no action (previous $1 m accrual reversed).
Outlook: Management did not provide forward guidance in the filing. Revenue growth persists but profitability deteriorated due to higher opex and one-time impairment; cash position remains strong.